Halozyme Therapeutics (HALO) Tops Q4 EPS by 3c; Guides FY15 Revs
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $38.64 +2.20%
Revenue Growth %: +27.7%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
MAXN, CSTR, ACU, More
Revenue Growth %: +27.7%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $30.38 million versus the consensus estimate of $25.6 million.
Halozyme Therapeutics sees FY2015 EPS of $85.00-$95.00, versus the consensus of $97.70.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Growth isn't weak enough to truly undercut inflation pressures - BMO
- Schlumberger (SLB) earnings in-line, revenue beats expectations
- Park National Corp. (PRK) Tops Q1 EPS by 36c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
